Related Experiment Video
Updated: Jan 6, 2026
07:37
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
3.5K
β2-Microglobulin: A potential novel prognostic indicator for neuroblastoma
Yan Lei1,2, Jianjun Zhu3, Xiaoning Liu4
1Kunming Medical University, No. 1168 Chunrong West Road, Yuhua Street, Chenggong District, Kunming, 650500, Yunnan, China.
Summary
Beta-2 microglobulin (β2M) shows significant prognostic value in pediatric neuroblastoma. High β2M expression correlates with improved three-year survival rates, offering a potential biomarker for risk stratification and treatment decisions.
Area of Science:
- Pediatric Oncology
- Biomarker Discovery
- Cancer Prognostics
Background:
- Neuroblastoma is a common childhood cancer with difficult prognosis assessment.
- Intermediate- to high-risk neuroblastoma patients require reliable prognostic markers.
- This study explored beta-2 microglobulin (β2M) as a predictive biomarker.
Purpose of the Study:
- To investigate the prognostic value of β2M in intermediate- to high-risk neuroblastoma.
- To assess β2M's potential as a clinical biomarker for patient outcomes.
Main Methods:
- Retrospective analysis of 40 neuroblastoma patients (2018-2021).
- Analysis of peripheral blood and tissue samples.
- Biomarker detection using flow cytometry and RT-qPCR.
Main Results:
- β2M was the sole biomarker significantly linked to neuroblastoma prognosis.
- Higher β2M expression correlated with significantly better three-year survival (P < 0.01).
- Logistic regression and ROC analysis showed β2M's predictive ability comparable to neuron-specific enolase.
Conclusions:
- β2M demonstrates significant prognostic value in intermediate- to high-risk neuroblastoma.
- β2M may serve as an effective biomarker for clinical prognosis and individualized treatment.
- Further research is needed to validate β2M in diverse populations and for treatment monitoring.
